NextCure (NXTC) Total Current Liabilities (2018 - 2026)
NextCure (NXTC) posted quarterly Total Current Liabilities of $6.9 million for Q1 2026, up 20.05% year-over-year from $5.7 million in Q1 2025, and down 34.78% quarter-over-quarter from $10.6 million in Q4 2025.
NextCure (NXTC) Total Current Liabilities (2018 - 2026) Analysis & Trends
NextCure's Total Current Liabilities history runs 9 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 20.05% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 20.05% YoY), while the FY2025 annual figure was $10.6 million, up 10.36% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $6.9 million, down from $10.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $11.0 million in Q3 2025, with the low at $5.7 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $7.8 million (2023), against an average of $8.1 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities soared 52.94% in 2024, then sank 40.1% in 2025.
- NextCure's Total Current Liabilities stood at $9.1 million in 2022, then retreated by 24.59% to $6.9 million in 2023, then soared by 39.1% to $9.6 million in 2024, then advanced by 10.36% to $10.6 million in 2025, then slumped by 34.78% to $6.9 million in 2026.
- Business Quant data shows NXTC's Total Current Liabilities at $6.9 million in Q1 2026, $10.6 million in Q4 2025, and $11.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 6.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.41 Mn |
| Mar 31, 2026 | 6.89 Mn |
| Dec 31, 2025 | 10.57 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Jun 30, 2025 | 10.78 Mn |
| Mar 31, 2025 | 5.74 Mn |
| Dec 31, 2024 | 9.57 Mn |
| Sep 30, 2024 | 8.67 Mn |
| Jun 30, 2024 | 10.83 Mn |
| Mar 31, 2024 | 9.58 Mn |
| Dec 31, 2023 | 6.88 Mn |
| Sep 30, 2023 | 6.55 Mn |
| Jun 30, 2023 | 7.82 Mn |
| Mar 31, 2023 | 6.27 Mn |
| Dec 31, 2022 | 9.13 Mn |
| Sep 30, 2022 | 5.89 Mn |
| Jun 30, 2022 | 5.70 Mn |
| Mar 31, 2022 | 6.42 Mn |
| Dec 31, 2021 | 6.61 Mn |
| Sep 30, 2021 | 7.38 Mn |